Compare CAE & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAE | RDY |
|---|---|---|
| Founded | 1947 | 1984 |
| Country | Canada | India |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 11.6B |
| IPO Year | N/A | N/A |
| Metric | CAE | RDY |
|---|---|---|
| Price | $34.23 | $12.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $33.75 | $16.90 |
| AVG Volume (30 Days) | 477.9K | ★ 1.2M |
| Earning Date | 02-12-2026 | 01-21-2026 |
| Dividend Yield | N/A | ★ 0.55% |
| EPS Growth | N/A | ★ 9.95 |
| EPS | ★ 0.97 | 0.79 |
| Revenue | $3,470,482,234.00 | ★ $3,851,623,984.00 |
| Revenue This Year | $6.40 | $6.12 |
| Revenue Next Year | $5.37 | $2.58 |
| P/E Ratio | $35.03 | ★ $16.22 |
| Revenue Growth | 9.12 | ★ 14.10 |
| 52 Week Low | $20.36 | $12.26 |
| 52 Week High | $34.24 | $16.17 |
| Indicator | CAE | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 76.45 | 27.01 |
| Support Level | $32.36 | $13.15 |
| Resistance Level | $33.48 | $13.30 |
| Average True Range (ATR) | 0.66 | 0.17 |
| MACD | 0.10 | -0.10 |
| Stochastic Oscillator | 98.96 | 0.40 |
CAE Inc provides training and aviation services, integrated enterprise solutions, in-service support, and crew-sourcing services. The company operations are managed through two segments: Civil Aviation which offers comprehensive training solutions for flight, cabin, maintenance, and ground personnel in commercial, business, and helicopter aviation, a complete range of flight simulation training devices, ab initio pilot training, and crew sourcing services, as well as aircraft flight operations solutions; and Defense and Security which is a world-wide training and simulation provider delivering scalable, platform-independent solutions that enable and enhance force readiness and security. It generates the majority of its revenue from the Civil Aviation segment.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.